The effects of lithium sulphate following acute administration to Wistar rats in therapeutic and toxic doses were investigated, using as markers the levels and turnover of brain, kidney and liver nucleotides. Adenine-and guanine-dependent nucleotides were assayed concomitantly, using a highperformance liquid chromatographic method. Following acute administration, lithium's effects on 3',5'-cAMP levels were more significant at hepatic and cerebral level, in a dose-dependant manner. The effect on 3',5'-cGMP had tissue specificity and was not dose-dependant. It might be possible that 3',5'-cGMP is a better indicator of lithium toxicity than 3',5'-cAMP.
INTRODUCTION
Lithium is used as a major drug in psychiatry, especially in the treatment and prophylaxy of bipolar affective disorder, also in antidepressant-resistant patients, as well as in intemal medicine.Despite almost 40 years of clinical use and scientific investigation, neither the pharmacological actions of lithium at therapeutic doses, nor its mechanisms of toxicity have yet been completely established.
According to the most recent theories, the pharmacological and some of the toxic effects of lithium are related to its interaction with the signal transduction pathways5'. Li has been shown to interfere both with G-proteins and with the turnover of second messengers like 3',5'-cAMP, 3',5'-cGMP and the molecules dedved from phosphatidylinositol 4,5-bisphosphate (PIP2) pathway7-.
Generally, lithium is known to inhibit the adenylate cyclase (AC) which catalyses the formation of 3',5'-cAMP, a second messenger. The differential inhibition of receptor-specific AC species could provide an unifying hypothesis for the therapeutic and adverse effects of the drug5. Thus, the inhibition of adrenoceptor-activated cyclase at low lithium concentration could be seen as therapeutic effect, while the inhibition of other systems, e.g. dopamine-stimulated, ADH-stimulated and TSH-stimulated cyclase Lithium effect on 3',5'-cGMP was studied only in the brain and at therapeutic doses, without correlating the results with the effects on other cyclic nucleotides 5' Considering the role of the second messengers in the developement of toxic phenomena, we investigated the effects of lithium sulphate following acute administration to Wistar rats, at therapeutic and toxic doses, using as markers the level and tumover of brain, kidney and liver nucleotides. Reagents. Reagent-grade nucleotides (GTP, GDP, ATP, ADP, 5'-AMP, 3'-AMP, 3',5'-cAMP, 3',5'-cGMP) and NH,H2PO, were purchased from Sigma and methanol of HPLC purity from Merck.
MATERIALS AND METHODS

Animals
RESULTS AND DISCUSSION
The identification of the nucleotides in the biological samples was done according to their retention time (tR) and the order of elution comparared with standards' separation ( Fig.l) . Cochromatograms of each sample with different standard nucleotides were also performed for a better identification of peaks.
For the quantitative analysis, the chromatographic peaks were integrated and from their area, the percentage of each nucleotide was determined. Fig.2 shows the separation of adenine-and guanine nucleotides from brain extracts. In controls (Fig.2.A. ) the following nucleotides were identified: GTP co-eluted with GDP, ATP, ADP, 5'-AMP, 3 '-AMP and 3',5'-cGMP. The signal with tR = 12.33 min corresponding to 3',5'-cAMP in standard mixture was not present in this extract. Taking into account the fact that only basal, unstimulated AC activity was investigated and 3',5'-cAMP (whose levels are normally below 10
.6 M) is metabolized within seconds to 5'-AMPe'7, we considered that the effect of lithium on this second messenger could be appreciated only by the variation of 5'-AMP levels. Li2SO4 administration at increasing doses (from 2 to 10 mmol/kg) resulted in the disappearance of the peak with tR = 9.92 min (corresponding to 3',5'-cGMP) and a decrease of the peak surface with tR = 9.09 min, corresponding to 5'-AMP (Fig.2 B,C,D) .
Iol. 3, No. 3, 1996 "In livo" Effects of Lithium Sulphate Figure 2 . HPLC separation of nucleotides in brain homogenates, before (A) and after oral administration of 2 (B), 6 (C) and 10 (D) mmol Li/kg b.w.
The HPLC separation of adenine-and guanine nucleotides from kidney homogenates is depicted in Fig.3 . From the controls' chromatograms were identified" GTP co-eluted with GDP, ATP, ADP, 5'-AMP, 3'-AMP and 3',5'-cGMP ( Fig.3.A) . In the chromatograms from Li2SO,-treated rats an increase of the surface of the peaks with tR = 9.32 min (corresponding to 3'-AMP) and with tR=9.93 minutes, (corresponding to 3',5'-cGMP) was observed ( Fig.3 B,C,D) . before (A) and after oral Fig.4 shows the separation of adenine-and guanine nucleotides from liver homogenates. In controls (Fig.4 .A) the following nucleotides were identified GTP co-eluted with GDP, ATP, ADP, 5'-AMP, 3 '-AMP and a small peak corresponding to 3',5'-cGMP. In the chromatograms from Li2SO4-treated animals (Fig.4 B,C,D) the increase of the peak area corresponding to 3',5'-cGMP and a gradual decrease until disappearance of the peak with tF=9.12 min, (corresponding to 5'-AMP) was observed. Unlike other studies, where the analysis of the cyclic nucleotides was performed by [18] [19] [20] mdioimmunoassay methods our method allowed the concomitant separation and evaluation of both adenine-and guanine-dependant nucleotides in tissues. Although 3',5'-cAMP was not identified in these tissues, dose-dependent variations in the levels of its stable metabolite, 5'-AMP were observed. So, the acute administration of lithium induced a decrease of 5'-AMP levels in brain, which is more important when the dose of 2 mmol Li//kg ( extrapolated from the human therapeutic doses) was administered. Figures 5-6-7. Tumover of adenine-and guanine nucleotides in rat brain (5), kidney (6) and liver (7) (Fig.6) .
The most important changes in the percentage of adenine-and guanine-dependent nucleotides were observed at the hepatic level, in a dose-dependant manner. Doses of 2 mmol Li//kg had a reduced effect on 3',5'-cAMP level, while the toxic doses of 6 and 10 mmol Li//kg inhibited the formation of 3',5'-cAMP (Fig.7) . The explanation could be due to hepatocyte's specificity, with a high metabolic tumover, more susceptible comparatively to other organs.
Our study confirmed that the stimulation of 3',5'-cGMP formation by lithium might have important implications in its mechanism of toxicity. It is supposed that Li may increase 3',5'-cGMP via modulation of the free fatty acids and their oxidized metabolites, especially prostaglandine 52 and the associated free radicals which are known to activate guanylate cyclase.
Following acute administration, lithium's effects on 3',5'-cAMP were more significant at hepatic and brain level in a dose-dependant manner, while the effects on 3',5'-cGMP were different from brain to liver and kidney, respectively and were not dose-dependant. Thus, the relationships between 3',5'-cGMP and 3',5'-cAMP were dependant on the. tissue investigated and in consequence, on the receptors and neurotransmiters involved.
Considering the different tumovers of 3',5'-cGMP and 3',5'-cAMP in different tissues, we suggest their use as relevant markers of lithium activity. Taking into account the most significant variations of 3',5'-cGMP in all investigated tissues, it might be prefered as a better indicator of lithium toxicity.
